Immune reconstitution in HIV-1-infected individuals treated with potent antiretroviral therapy

Journal of Investigative Dermatology Symposium Proceedings

Volumn 6, Issue 3, 2001, Pages 212-218

  Connick, Elizabeth ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antiretroviral therapy; CD4+ T lymphocytes; HIV 1; Immune reconstitution

Indexed keywords

CD4+ T LYMPHOCYTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0035749835     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202x.2001.00049.x     Document Type: Article

References (31)

1. Aberg JA, Yajko DM, Jacobson MA: Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis 178:1446-1449, 1998
2. Albrecht H, Hoffmann C, Degen O, et al: Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 12:1149-1154, 1998
3. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A: Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 14:761-770, 2000
4. Autran B, Carcelain G, Li TS, et al: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116, 1997
5. Baldeweg T, Catalan J: Remission of progressive multifocal leukoencephalopathy after antiretroviral therapy. Lancet 349:1554-1555, 1997
6. Baqi M, Kucharczyk W, Walmsley SL: Regression of progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 11:1526-1527, 1997
7. Barassi C, De Santis C, Pastori C, et al: Early production of HIV-1 neutralising antibodies in patients following highly active antiretroviral treatment (HAART) during primary HIV infection. J Biol Regulators Homeostatic Agents 14:68-74, 2000
8. Bell EB, Sparshott SM: Interconversion of CD45R subsets of CD4 T cells in vivo. Nature 348:163-166, 1990
9. Berzofsky JA, Bensussan A, Cease KB, et al: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune human. Nature 334:706-708, 1988
10. Bisset LR, Cone RW, Huber W, et al: Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. AIDS 12:2115-2123, 1998
11. Blatt SP, Hendrix CW, Butzin CA, et al: Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Int Med 119:177-184, 1993
12. Borrow P, Lewicki H, Wei X, et al: Antiviral pressure exerted by HIV-1-specific T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med 3:205-211, 1997
13. Brodt HR, Kamps BS, Gute P, et al: Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11:1731-1738, 1997
14. Bucy RP, Hockett RD, Derdeyn CA, et al: Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 103:1391-1398, 1999
15. Cameron DW, Heath-Chiozzi M, Danner S, et al: Randomised, placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351:543-549, 1998
16. Carpenter CC, Cooper DA, Fischl MA, et al: Antiretroviral therpay in adults. Updated recommendations of the international AIDS society-USA panel. JAMA 283:381-390, 2000
17. Carr A, Cooper DA: Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349:995-996, 1997
18. Carr A, Marriott D, Field A, et al: Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 351:256-261, 1998
19. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report 10:38, 1999a
20. Centers for Disease Control and Prevention: 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 48 (RR10):1-59, 1999b
21. Chien JW, Johnson JL: Paradoxical reactions in HIV and pulmonary TB. Chest 114:933-936, 1998
22. Cinque P, Casari S, Bertelli D: Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy. N Engl J Med 339:848-849, 1998
23. Clerici M, Stocks NI, Zajac RA, et al: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic human immunodeficiency virus-seropositive patients: independence of CD4+ cell numbers and clinical staging. J Clin Invest 84:1892-1899, 1989
24. Collier AC, Coombs RW, Schoenfeld DA, et al: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 334:1011-1017, 1996
25. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D: HIV-1 nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397-401, 1998
26. Conant MA, Opp KM, Poretz D, et al: Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS 11:1300-1301, 1997
27. Connick E, Lederman MM, Kotzin BL, et al: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 181:358-363, 2000
28. Connors M, Kovacs JA, Krevat S, et al: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 3:533-540, 1997
29. Correll PK, Law MG, McDonald AM, et al: HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 169:469-472, 1998
30. D'Aquila RT, Hughes MD, Johnson VA, et al: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 124:1019-1030, 1996
31. Dalod M, Harzic M, Pellegrin I, et al: Evolution of cytotoxic T lymphocyte responses to human imniunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 178:61-69, 1998